{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T14:32:58Z","timestamp":1794493978165,"version":"4.9.1"},"reference-count":91,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.euroneuro.2022.10.005","type":"journal-article","created":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T06:24:42Z","timestamp":1667543082000},"page":"1-10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Antidepressant discontinuation syndrome: A state-of-the-art clinical review"],"prefix":"10.1016","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9647-0853","authenticated-orcid":false,"given":"M.","family":"Fornaro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6930-8105","authenticated-orcid":false,"given":"C.I.","family":"Cattaneo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4415-5058","authenticated-orcid":false,"given":"D.","family":"De Berardis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6055-3537","authenticated-orcid":false,"given":"F.V.","family":"Ressico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Martinotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0548-0053","authenticated-orcid":false,"given":"E.","family":"Vieta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2022.10.005_bib0001","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1600-0447.1959.tb07529.x","article-title":"Tofranil-treatment of endogenous depressions","volume":"34","author":"Andersen","year":"1959","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0002","unstructured":"APA, 2010. American psychiatric association practice guideline for the treatment of patients with major depressive disorder (3rd ed.)."},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0003","unstructured":"APA, 2019. APA clinical practice guideline for the treatment of depression across three age cohort."},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0004","series-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"2022"},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0005","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1176\/appi.ajp.2010.09060880","article-title":"Illness risk following rapid versus gradual discontinuation of antidepressants","volume":"167","author":"Baldessarini","year":"2010","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0006","doi-asserted-by":"crossref","first-page":"7275","DOI":"10.4088\/JCP.v59n0509b","article-title":"FINISH: remembering the discontinuation syndrome","volume":"59","author":"Berber","year":"1998","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0007","first-page":"8","article-title":"Physiologic mechanisms underlying the antidepressant discontinuation syndrome","volume":"67","author":"Blier","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0008","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S2215-0366(18)30100-7","volume":"5","author":"Bockting","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0009","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1124\/pr.117.014977","article-title":"International union of basic and clinical pharmacology CIV: the neurobiology of treatment-resistant depression: from antidepressant classifications to novel pharmacological targets","volume":"70","author":"Caraci","year":"2018","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0010","first-page":"25","article-title":"Use of antidepressants: expansion beyond depression and anxiety","volume":"4","author":"Cascade","year":"2007","journal-title":"Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0011","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1017\/S1092852919001378","article-title":"Commentary letter on \u201cRevitalizing monoamine oxidase inhibitors: a call for action","volume":"25","author":"Cattaneo","year":"2020","journal-title":"CNS Spectr."},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0012","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1139\/jpn.0427","article-title":"The therapeutic role of 5-HT1A and 5-HT2A receptors in depression","volume":"29","author":"Celada","year":"2004","journal-title":"J. Psychiatry Neurosci."},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0013","doi-asserted-by":"crossref","first-page":"565","DOI":"10.3390\/ph15050565","article-title":"A focus on abuse\/misuse and withdrawal issues with Selective Serotonin Reuptake Inhibitors (SSRIs): analysis of both the European EMA and the US FAERS pharmacovigilance databases","volume":"15","author":"Chiappini","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0014","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1159\/000371865","article-title":"New classification of selective serotonin reuptake inhibitor withdrawal","volume":"84","author":"Chouinard","year":"2015","journal-title":"Psychother. Psychosom."},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0015","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1176\/appi.focus.16407","article-title":"Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis","volume":"16","author":"Cipriani","year":"2018","journal-title":"Focus"},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0016","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1159\/000506868","article-title":"Acute and persistent withdrawal syndromes following discontinuation of psychotropic medications","volume":"89","author":"Cosci","year":"2020","journal-title":"Psychother. Psychosom."},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0017","first-page":"95","article-title":"The diagnostic clinical interview for drug withdrawal 1 (DID-W1)\u2013new symptoms of Selective Serotonin Reuptake Inhibitors (SSRI) or Serotonin Norepinephrine Reuptake Inhibitors (SNRI): inter-rater reliability","volume":"53","author":"Cosci","year":"2018","journal-title":"Riv. Psichiatr."},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0018","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1097\/00004714-199610000-00003","article-title":"Serotonin reuptake inhibitor withdrawal","volume":"16","author":"Coupland","year":"1996","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0019","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.addbeh.2018.08.027","article-title":"A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: are guidelines evidence-based?","volume":"97","author":"Davies","year":"2019","journal-title":"Addict. Behav."},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0020","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1159\/000492693","article-title":"Discontinuing antidepressant drugs: lesson from a failed trial and extensive clinical experience","volume":"87","author":"Fava","year":"2018","journal-title":"Psychother. Psychosom."},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0021","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1159\/000491524","article-title":"Withdrawal symptoms after serotonin-noradrenaline reuptake inhibitor discontinuation: systematic review","volume":"87","author":"Fava","year":"2018","journal-title":"Psychother. Psychosom."},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0022","doi-asserted-by":"crossref","first-page":"21831","DOI":"10.4088\/JCP.19com12794","article-title":"Understanding and managing withdrawal syndromes after discontinuation of antidepressant drugs","volume":"80","author":"Fava","year":"2019","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0023","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1159\/000370338","article-title":"Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review","volume":"84","author":"Fava","year":"2015","journal-title":"Psychother. Psychosom."},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0024","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.phrs.2018.10.025","article-title":"The emergence of loss of efficacy during antidepressant drug treatment for major depressive disorder: an integrative review of evidence, mechanisms, and clinical implications","volume":"139","author":"Fornaro","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1744-859X-8-21","article-title":"Medicine and psychiatry in Western culture: ancient Greek myths and modern prejudices","volume":"8","author":"Fornaro","year":"2009","journal-title":"Ann. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0026","doi-asserted-by":"crossref","DOI":"10.1177\/2045125321991274","article-title":"What I have learnt from helping thousands of people taper off antidepressants and other psychotropic medications","volume":"11","author":"Framer","year":"2021","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0027","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/archpsyc.1991.01810330075011","article-title":"Conceptualization and rationale for consensus definitions of terms in major depressive disorder: remission, recovery, relapse, and recurrence","volume":"48","author":"Frank","year":"1991","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0028","doi-asserted-by":"crossref","first-page":"E747","DOI":"10.1503\/cmaj.160991","article-title":"Antidepressant discontinuation syndrome","volume":"189","author":"Gabriel","year":"2017","journal-title":"CMAJ"},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0029","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1017\/S109285291200003X","article-title":"Practical guide for prescribing MAOIs: debunking myths and removing barriers","volume":"17","author":"Grady","year":"2012","journal-title":"CNS Spectr."},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0030","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1471-1842.2009.00848.x","article-title":"A typology of reviews: an analysis of 14 review types and associated methodologies","volume":"26","author":"Grant","year":"2009","journal-title":"Health Inf. Libr. J."},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0031","first-page":"17","article-title":"Newer antidepressants and the discontinuation syndrome","volume":"58","author":"Haddad","year":"1997","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0032","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1177\/026988119801200311","article-title":"The SSRI discontinuation syndrome","volume":"12","author":"Haddad","year":"1998","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0033","first-page":"447","article-title":"Recognising and managing antidepressant discontinuation symptoms","volume":"13","author":"Haddad","year":"2007","journal-title":"Minaprine New Psychotr. Drug Act. Affect. Disord. Int. Symp."},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0034","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S0006-3223(03)00528-6","article-title":"Neurobiology of antidepressant withdrawal: implications for the longitudinal outcome of depression","volume":"54","author":"Harvey","year":"2003","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0035","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/hup.2429","article-title":"New insights on the antidepressant discontinuation syndrome","volume":"29","author":"Harvey","year":"2014","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0036","doi-asserted-by":"crossref","DOI":"10.1177\/2045125320921694","article-title":"How effective are antidepressants for depression over the long term? A critical review of relapse prevention trials and the issue of withdrawal confounding","volume":"10","author":"Hengartner","year":"2020","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0037","doi-asserted-by":"crossref","DOI":"10.1177\/2045125320980573","article-title":"Protracted withdrawal syndrome after stopping antidepressants: a descriptive quantitative analysis of consumer narratives from a large internet forum","volume":"10","author":"Hengartner","year":"2020","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0038","first-page":"355","article-title":"Antidepressant withdrawal and rebound phenomena","volume":"116","author":"Henssler","year":"2019","journal-title":"Dtsch. Arztebl. Int."},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0039","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/S2215-0366(19)30032-X","article-title":"Tapering of SSRI treatment to mitigate withdrawal symptoms","volume":"6","author":"Horowitz","year":"2019","journal-title":"Lancet Psychiatry"},{"issue":"5","key":"10.1016\/j.euroneuro.2022.10.005_bib0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1192\/bja.2021.62","article-title":"Distinguishing relapse from antidepressant withdrawal: clinical practice and antidepressant discontinuation studies","volume":"28","author":"Horowitz","year":"2022","journal-title":"BJPsych Adv."},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0041","first-page":"60","article-title":"SSRIs and SNRIs: a review of the discontinuation syndrome in children and adolescents","volume":"20","author":"Hosenbocus","year":"2011","journal-title":"J. Can. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0042","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.comppsych.2010.08.005","article-title":"Comorbidities and factors related to discontinuation of pharmacotherapy among outpatients with major depressive disorder","volume":"52","author":"Hung","year":"2011","journal-title":"Compr. Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0043","first-page":"l6103","article-title":"NICE updates antidepressant guidelines to reflect severity and length of withdrawal symptoms","volume":"367","author":"Iacobucci","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0044","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3109\/13814788.2013.838670","article-title":"Why do patients discontinue antidepressant therapy early? A qualitative study","volume":"20","author":"Jaffray","year":"2014","journal-title":"Eur. J. Gen. Pract."},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0045","doi-asserted-by":"crossref","first-page":"70","DOI":"10.9758\/cpn.2022.20.1.70","article-title":"Long-term safety and efficacy of esketamine nasal spray plus an oral antidepressant in patients with treatment-resistant depression\u2013an Asian sub-group analysis from the SUSTAIN-2 study","volume":"20","author":"Jeon","year":"2022","journal-title":"Clin. Psychopharmacol. Neurosci."},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0046","doi-asserted-by":"crossref","first-page":"4538","DOI":"10.4088\/JCP.19com13047","article-title":"Discontinuing antidepressants: how can clinicians guide patients and drive research?","volume":"80","author":"Jha","year":"2019","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0047","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1176\/appi.ajp.2018.18060692","article-title":"When discontinuing SSRI antidepressants is a challenge: management tips","volume":"175","author":"Jha","year":"2018","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0048","doi-asserted-by":"crossref","DOI":"10.1177\/2045125320922738","article-title":"Conversations with clients about antidepressant withdrawal and discontinuation","volume":"10","author":"Karter","year":"2020","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0049","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1055\/a-1330-8587","article-title":"Effects of discontinuation of drugs used for augmentation therapy on treatment outcomes in depression: a systematic review and meta-analysis","volume":"54","author":"Kato","year":"2021","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.euroneuro.2019.12.117","article-title":"Placebo-to be or not to be? Are there really alternatives to placebo-controlled trials?","volume":"32","author":"Krol","year":"2020","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0051","first-page":"11","article-title":"Antidepressant discontinuation: a review of the literature","volume":"58","author":"Lejoyeux","year":"1997","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0052","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1136\/pgmj.74.875.529","article-title":"Antidepressants are not drugs of abuse or dependence","volume":"74","author":"Lichtigfeld","year":"1998","journal-title":"Postgrad. Med. J."},{"issue":"11","key":"10.1016\/j.euroneuro.2022.10.005_bib0053","article-title":"Predictors of successful discontinuation of antipsychotics and antidepressants","volume":"1","author":"Lincoln","year":"2021","journal-title":"Psychol. Med."},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0054","doi-asserted-by":"crossref","unstructured":"Lunghi, C., Dugas, M., Leclerc, J., Poluzzi, E., Martineau, C., Carnovale, V., St\u00e9fan, T., Blouin, P., L\u00e9pine, J., Jalbert, L., Espinoza Suarez, N.R., Svyntozelska, O., Dery, M.P., Ekanmian, G., Nogueira, D.M., Akinola, P.S., Skidmore, B., LeBlanc, A., 2022. Global prevalence of antidepressant utilization in the community: a protocol for a systematic review. medRxiv, 2022.2002.2017.22271152.","DOI":"10.1101\/2022.02.17.22271152"},{"issue":"21","key":"10.1016\/j.euroneuro.2022.10.005_bib0055","first-page":"365","article-title":"Antidepressant withdrawal guidance must be updated to reflect evidence","volume":"5","author":"Mahase","year":"2019","journal-title":"Br. Med. J."},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0056","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/0004867420979353","article-title":"The 2020 royal Australian and New Zealand college of Psychiatrists clinical practice guidelines for mood disorders","volume":"55","author":"Malhi","year":"2021","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0057","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1370\/afm.2336","article-title":"Managing antidepressant discontinuation: a systematic review","volume":"17","author":"Maund","year":"2019","journal-title":"Ann. Fam. Med."},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0058","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1176\/appi.ajp.161.5.826","article-title":"Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C] DASB positron emission tomography study","volume":"161","author":"Meyer","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0059","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1159\/000446441","article-title":"Clonidine use in psychiatry: panacea or panache?","volume":"98","author":"Naguy","year":"2016","journal-title":"Pharmacology"},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0060","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1177\/0269881109359094","article-title":"Antidepressant discontinuation manic states: a critical review of the literature and suggested diagnostic criteria","volume":"25","author":"Narayan","year":"2011","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0061","unstructured":"NICE, 2009. Depression in adults: recognition and management."},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0062","unstructured":"NICE, 2022. Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults."},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0063","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1111\/j.1360-0443.2011.03686.x","article-title":"What is the difference between dependence and withdrawal reactions? A comparison of benzodiazepines and selective serotonin re-uptake inhibitors","volume":"107","author":"Nielsen","year":"2012","journal-title":"Addiction"},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0064","volume":"20","author":"Papp","year":"2018"},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0065","volume":"36","author":"Pies","year":"2019"},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0066","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jad.2014.11.008","article-title":"Cognitive tolerability following successful long term treatment of major depression and anxiety disorders with SSRi antidepressants","volume":"173","author":"Popovic","year":"2015","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0067","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1001\/archpsyc.1984.01790140028003","article-title":"Duration of antidepressant drug treatment: what is an adequate trial?","volume":"41","author":"Quitkin","year":"1984","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0068","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.addbeh.2018.08.021","article-title":"Staying on, and coming off, antidepressants: the experiences of 752 UK adults","volume":"88","author":"Read","year":"2019","journal-title":"Addict. Behav."},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0069","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3389\/fphar.2013.00045","article-title":"Selective serotonin reuptake inhibitor antidepressant treatment discontinuation syndrome: a review of the clinical evidence and the possible mechanisms involved","volume":"4","author":"Renoir","year":"2013","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0070","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.jad.2013.02.040","article-title":"Unplanned pregnancy and discontinuation of SSRIs in pregnant women with previously treated affective disorder","volume":"150","author":"Roca","year":"2013","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0071","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0006-3223(98)00126-7","article-title":"Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial","volume":"44","author":"Rosenbaum","year":"1998","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0072","first-page":"9393","article-title":"Introduction\/antidepressant discontinuation syndrome: an update on serotonin reuptake inhibitors","volume":"58","author":"Schatzberg","year":"1997","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0073","first-page":"19284","article-title":"Serotonin reuptake inhibitor discontinuation syndrome: a hypothetical definition","volume":"58","author":"Schatzberg","year":"1997","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0074","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1192\/bjp.bp.107.048371","article-title":"Antidepressant-induced jitteriness\/anxiety syndrome: systematic review","volume":"194","author":"Sinclair","year":"2009","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0075","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1590\/1516-4446-2020-0935","article-title":"How can we improve antidepressant adherence in the management of depression? A targeted review and 10 clinical recommendations","volume":"43","author":"Solmi","year":"2020","journal-title":"Braz. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0091","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jad.2022.08.011","article-title":"Description of antidepressant withdrawal symptoms in clinical practice guidelines on depression: A systematic review","volume":"316","author":"S\u00f8rensen","year":"2022","journal-title":"J Affect Disord"},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0076","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0165-0327(98)00221-3","article-title":"Mechanism of action of serotonin selective reuptake inhibitors: serotonin receptors and pathways mediate therapeutic effects and side effects","volume":"51","author":"Stahl","year":"1998","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0077","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s12325-021-02029-6","article-title":"Engaging patients with depression in treatment continuity","volume":"39","author":"Stein","year":"2022","journal-title":"Adv. Ther."},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0078","first-page":"24","article-title":"Identification and treatment of antidepressant tachyphylaxis","volume":"11","author":"Targum","year":"2014","journal-title":"Innov. Clin. Neurosci."},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0079","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1177\/0269881107081550","article-title":"The effect of rate of antidepressant tapering on the incidence of discontinuation symptoms: a randomised study","volume":"22","author":"Tint","year":"2008","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0080","series-title":"Withdrawal, Dependence and Adverse Events of Antidepressants: Lessons From Patients and Data","first-page":"137","author":"Tomlinson","year":"2019"},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0081","unstructured":"Van den Eynde, V., Abdelmoemin, W.R., Abraham, M.M., Amsterdam, J.D., Anderson, I.M., Andrade, C., Baker, G.B., Beekman, A.T., Berk, M., Birkenh\u00e4ger, T.K., 2022. The prescriber's guide to classic MAO inhibitors (phenelzine, tranylcypromine, isocarboxazid) for treatment-resistant depression. CNS Spectr., 1-14."},{"issue":"15","key":"10.1016\/j.euroneuro.2022.10.005_bib0082","article-title":"Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults","volume":"4","author":"Van Leeuwen","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0083","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the global burden of disease study 2019","volume":"396","author":"Vos","year":"2020","journal-title":"Lancet N. Am. Ed."},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0084","first-page":"449","article-title":"Antidepressant discontinuation syndrome","volume":"74","author":"Warner","year":"2006","journal-title":"Am. Fam. Physician"},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0085","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1177\/2045125315612334","article-title":"A review of the management of antidepressant discontinuation symptoms","volume":"5","author":"Wilson","year":"2015","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0086","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ejphar.2018.04.003","article-title":"Understanding antidepressant discontinuation syndrome (ADS) through preclinical experimental models","volume":"829","author":"Zabegalov","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0087","doi-asserted-by":"crossref","first-page":"291","DOI":"10.4088\/JCP.v58n0702","article-title":"Discontinuation symptoms after treatment with serotonin reuptake inhibitors: a literature review","volume":"58","author":"Zajecka","year":"1997","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0088","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.euroneuro.2022.01.002","article-title":"Neuroscience-based nomenclature of psychotropics: progress report","volume":"57","author":"Zohar","year":"2022","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0089","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1016\/j.euroneuro.2015.08.019","article-title":"A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature","volume":"25","author":"Zohar","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2022.10.005_bib0090","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3949\/ccjm.89a.21020","article-title":"Discontinuing antidepressants: pearls and pitfalls","volume":"89","author":"Zwiebel","year":"2022","journal-title":"Cleve. Clin. J. Med."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X22008732?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X22008732?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T18:04:28Z","timestamp":1760378668000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X22008732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":91,"alternative-id":["S0924977X22008732"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2022.10.005","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antidepressant discontinuation syndrome: A state-of-the-art clinical review","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2022.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}